Daraxonrasib Generates $197.6 Million in Its First Five Weeks on the Market

Key Facts

RASONQUE, known generically as daraxonrasib, generated $197.6 million in net product sales revenue during the quarter ended September 30, 2026, according to Revolution Medicines’ results filed with the U.S. Securities and Exchange Commission. The company said the revenue reflected about five weeks of commercial availability, following U.S. Food and Drug Administration approval of the drug on August 26. The medicine is used to treat adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The early revenue came in a quarter that included only a limited portion of the marketing period, and the company said it also included initial inventory in distribution channels. The financial report therefore combines early product sales with a direct financing impact resulting from the approval.

The approval was based on the RASolute 302 study, a multicenter, open-label, randomized trial involving 500 patients, equally assigned to daraxonrasib or physician’s choice of standard chemotherapy. Median overall survival was 13.2 months among patients receiving the drug, compared with 6.7 months in the standard-therapy group, with a hazard ratio of 0.40 and a p-value below 0.0001. Median progression-free survival was also 7.2 months versus 3.6 months, with a hazard ratio of 0.49 and a p-value below 0.0001. The objective response rate was 30% among patients receiving the drug, compared with 11% with chemotherapy, and the p-value for the comparison was below 0.0001. The approval defines eligible patients by prior treatment or ineligibility for multi-agent systemic therapy, while the prescribing information recommends a 300 mg oral dose once daily until disease progression or unacceptable toxicity.

The FDA said the approval came about 6.5 months ahead of its target date, following review of the application through Project Orbis and the Real-Time Oncology Review pilot program. The approval comes against a backdrop of widespread disease: the agency estimates about 67,000 new pancreatic cancer cases annually in the United States, with pancreatic adenocarcinoma accounting for between 90% and 95% of those cases. The approved indication, however, is for metastatic disease, and patient eligibility is defined by prior systemic therapy or unsuitability for multi-agent treatment. These regulatory boundaries define the group to which the study results and approved use apply. The recommended dose is one tablet daily, with treatment continuing until disease progression or unacceptable toxicity.

The approval was also tied to financing arrangements between Revolution Medicines and Royalty Pharma. Revolution Medicines said it drew the first $250 million debt tranche in October after the drug’s approval triggered the agreement’s mandatory draw condition. The companies had announced in June 2025 a financing agreement totaling up to $2 billion, comprising up to $1.25 billion in synthetic royalty financing and up to $750 million in secured term loans. Under the terms, two additional loan tranches of $250 million each are available at the company’s option upon reaching annual sales targets. The first tranche is therefore tied to U.S. approval, while additional draws are tied to later sales milestones.

Royalty Pharma receives a tiered royalty on the drug’s sales, not the full value of sales: after the second financing tranche, the agreement provides for 4.55% of annual sales between $0 and $2 billion, 2.50% of the portion between $2 billion and $4 billion, and 1.00% of the portion between $4 billion and $8 billion. At a company conference in June 2026, one of its executives described $11 billion as an approximate consensus peak-sales estimate and said the royalty falls to zero above sales of $8 billion. That figure therefore does not mean Royalty Pharma expects to receive it as revenue or that the agreement gives it a royalty on all sales. On the company’s first-quarter earnings call in May, it estimated that potential annual royalties at peak could reach about $180 million based on the financing drawn at that time, and could reach $340 million if Revolution drew an additional $750 million in synthetic royalty financing. These are company estimates, not realized revenue, and actual receipts depend on sales and the financing and royalty terms.

On the European front, Revolution Medicines announced in October that the European Medicines Agency’s Committee for Medicinal Products for Human Use had issued a positive opinion recommending approval of daraxonrasib for eligible adults with metastatic pancreatic adenocarcinoma in the European Union. This follows U.S. approval in August and first-quarter launch revenue recorded through the end of September. The European opinion is the committee’s recommendation, while the U.S. development reported here is the approval granted by the FDA. The direct financial impact reported in the third quarter included product revenue and the debt tranche the company received in October. Additional financing tranches remain subject to the annual sales targets set out in the agreement.